Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration

Thomas A. Ciulla, Philip J Rosenfeld

Research output: Contribution to journalArticle

75 Scopus citations


The discovery of VEGF-A's role in the pathogenesis of neovascular ocular disease provided a strong rationale for the development of anti-VEGF-based therapies. There is now ample evidence that anti-VEGF therapies are viable treatment options for these diseases. Nevertheless, large, randomized controlled trials are still awaited to confirm early safety and efficacy findings from small, open-label prospective studies.

Original languageEnglish
Pages (from-to)166-174
Number of pages9
JournalCurrent Opinion in Ophthalmology
Issue number3
StatePublished - May 1 2009



  • Anti-vascular endothelial growth factor therapy
  • Bevacizumab
  • Neovascularization
  • Pegaptanib sodium
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this